AIRISE 02
Alternative Names: AIRISE-02; Intratumoral AIRISETMLatest Information Update: 19 Jun 2023
At a glance
- Originator PDX Pharmaceuticals
- Class Adjuvants; Antineoplastics; Immunotherapies; Small interfering RNA
- Mechanism of Action Immunomodulators; RNA interference; STAT3 transcription factor inhibitors; Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 13 Jun 2023 Pdx Pharmaceuticals plans a phase I/II trial for Solid tumors in 2023 (Pdx Pharmaceuticals website, June 2023)
- 14 Apr 2023 Preclinical trials in Solid tumours in USA (Intratumoural) as of June 2023 (Pdx Pharmaceuticals pipeline, June 2023)
- 14 Apr 2023 Pharmacodynamics and pharmacokinetics data from a preclinical study in Solid tumors presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)